The present invention discloses an improved process for O-demethylation of methoxy-substituted morphinan-6-one derivatives using boron-based complex as a demethylating boron complex in an inert reaction solvent.

Disclosed herein is a process for conversion of Oripavine to Thebaine in presence of dimethyl sulphate as methylating agent in sodium hydride as a base with good yield and purity in shorter reaction time.

The invention discloses compositions of eflornithine or its salt and prodrugs thereof in a dose range of 0.1 g to 26 g per day in different dosage forms, such as scored tablet, scored chewable tablet, capsule, oral solution and oral suspension, granules or powder composition in a sachet, intravenous infusion in the ...

Disclosed herein is an improved process for preparation of naltrexone decanoate under a monophasic medium using a single solvent by esterifying naltrexone with a decanoyl chloride in the presence of an organic base, , wherein the solvent is preferably cyclo-pentyl-methyl-ether (CPME) which is non-toxic in nature. Th...

The present invention relates to a novel, efficient, pot- and atom-economical, and industrially applicable process for converting morphine to noroxymorphone using reagents and solvents of lesser toxicity and lower cost with respect to those used in the prior art.

The present invention discloses a topical cream composition of eflornithine or its pharmaceutically acceptable salts or prodrugs thereof with lavender oil as penetration enhancer and other excipients, which is effective to reduce the rate of skin hair growth and studies pertaining to pharmacodynamic behaviour thereo...

The present invention provides a long term, liquid injectable pharmaceutically acceptable composition for sustained release of nalbuphine or a nalbuphine ester prodrug, or the pharmaceutically acceptable salts of nalbuphine, comprising one or more biocompatible non-aqueous solvents with one or more stabilizers, wher...

The present invention discloses a sustained release non-aqueous injectable composition of buprenorphine, its metabolite, its prodrug, or its salt thereof for the treatment of moderate-to-severe pain and opioid dependence. The non-aqueous injectable composition includes one or more biocompatible non-aqueous solvents,...

The invention discloses a biodegradable implant of buprenorphine used for the long term treatment of opioid drug addiction and pain relief. The biodegradable implant comprises buprenorphine embedded into a biodegradable polymer and a lubricant, wherein the implant biodegrades into the blood over the course of treatm...